多西他赛、表柔比星联合环磷酰胺对局部晚期乳腺癌辅助化学治疗不同周期的疗效研究

doi:10.3969/j.issn.1674-8115.2019.12.015

上海交通大学学报（医学版） ›› 2019, Vol. 39 ›› Issue (12): 1432-.doi: 10.3969/j.issn.1674-8115.2019.12.015

多西他赛、表柔比星联合环磷酰胺对局部晚期乳腺癌辅助化学治疗不同周期的疗效研究

王志威，王杰，魏敏，杨莉，邵玉国，籍敏，何奇

上海交通大学医学院附属国际和平妇幼保健院乳腺科，上海市胚胎源性疾病重点实验室，上海市临床重点专科（建设项目）——“强主体”妇产科，上海 200030

出版日期:2019-12-28 发布日期:2020-02-06
通讯作者: 何奇，电子信箱：doc_hq@126.com。
作者简介:王志威（1983—）博士，主治医师；电子信箱：docwang@yeah.net。
基金资助:
国际和平妇幼保健院院级课题（GFY5502）；国际和平妇幼保健院优秀青年医师培育计划（GFY9307）

Comparison of therapeutic effects between different cycles of docetaxel, epirubicin and cyclophosphamide regime on adjuvant chemotherapy of locally advanced breast cancer

WANG Zhi-wei, WANG Jie, WEI Min, YANG Li, SHAO Yu-guo, JI Min, HE Qi

Department of Breast, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Embryo Original Diseases; Shanghai Municipal Key Clinical Specialty, Shanghai 200030, China

Online:2019-12-28 Published:2020-02-06
Supported by:
Fund of International Peace Maternity and Child Health Hospital，GFY5502 ; Fund of Excellent Young Physician Cultivation Program of International Peace Maternity and Child Health Hospital, GFY9307

摘要/Abstract

摘要： 目的·比较TEC方案（多西他赛+表柔比星+环磷酰胺）8周期和6周期对局部晚期乳腺癌术后辅助化学治疗（化疗）效果和不良反应的差异。方法·回顾性分析2008年4月—2015年4月于上海交通大学医学院附属国际和平妇幼保健院治疗的腋窝淋巴结转移≥4 枚的局部晚期乳腺癌患者66例。按照化疗周期的不同将患者分为2组，观察组（TEC×8组）（n31）和对照组（TEC×6组）（n35）。比较2组患者的3年总生存率、无病生存率的差异，以及2组患者发生骨髓抑制、发热及肝功能异常等不良反应的差异。组间比较采用χ2检验，生存分析采用Kaplan-Meier法。结果·观察组的3年总生存率为93.5%，对照组为91.4%，2组比较差异无统计学意义（P0.716）。观察组的3年无病生存率为87.1%，对照组为85.7%，2组比较差异无统计学意义（P0.855）。观察组患者Ⅲ度或Ⅳ度骨髓抑制的发生率为90.3%，对照组为65.7%，2组比较差异有统计学意义（P0.017）。观察组发热的发生率为16.1%，对照组为14.3%，2组比较差异无统计学意义（P0.835）。观察组肝功能异常发生率为77.4%，对照组为85.7%，2组比较差异无统计学意义（P0.383）。结论·TEC×8方案与TEC×6方案相比，未能提高局部晚期乳腺癌患者的总生存率和无病生存率，2组发热和肝功能异常的发生率也无差异，但TEC×8方案显著增加Ⅲ度或Ⅳ度骨髓抑制的发生率。

关键词: 多西他赛, 表柔比星, 环磷酰胺, 乳腺癌, 化学治疗, 疗效, 不良反应

Abstract:

Objective · To compare the therapeutic effects and adverse effects between regimes TEC (docetaxel, epirubicin and cyclophosphamide)×8 and TEC×6 on the adjuvant chemotherapy of locally advanced breast cancer patients. Methods · Sixty-six locally advanced breast cancer patients with at least 4 positive lymph nodes were retrospectively selected in the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine April 2008 to April 2015. Patients were divided into TEC×8 regime group (n31) and TEC×6 regime group (n35) according to the cycles that were given to the patients. Three-year overall survival (OS) and 3-year disease free survival (DFS) rate of patients in these two groups were compared. The incidence of myelosuppression, fever and liver function injury were also compared between patients in TEC×8 regime group and TEC×6 regime group. Chi square test (χ2) was used for comparison between two groups. Kaplan-Meier method was adopted to perform survival analysis. Results · No significant difference was found in 3-year OS rate between TEC×8 regime group (93.5%) and TEC×6 regime group (91.4%) (P0.716), and no significant difference was found in 3-year DFS rate between TEC×8 regime group (87.1%) and TEC×6 regime group (85.7%) (P0.855). The incidence of grade Ⅲ/Ⅳmyelosuppression of patients in TEC×8 regime group (90.3%) was significantly higher than that in TEC×6 regime group (65.7%) (P0.017). No significant difference was found in the incidence of fever between TEC×8 regime group (16.1%) and TEC×6 regime group (14.3%) (P0.835). There was no significant difference in the incidence of liver function injury between TEC×8 regime group (77.4%) and TEC×6 regime group (85.7%) (P0.383). Conclusion · There is no significant difference in OS or DFS rate between TEC×8 regime and TEC×6 regime in adjuvant chemotherapy of locally advanced breast cancer, neither is in the incidence of fever and liver function injury. However, grade Ⅲ/Ⅳ myelosuppression more frequently occurs in TEC×8 regime group.

Key words: docetaxel, epirubicin, cyclophosphamide, breast cancer, chemotherapy, therapeutic effect, adverse effect

王志威，王杰，魏敏，杨莉，邵玉国，籍敏，何奇. 多西他赛、表柔比星联合环磷酰胺对局部晚期乳腺癌辅助化学治疗不同周期的疗效研究[J]. 上海交通大学学报（医学版）, 2019, 39(12): 1432-.

WANG Zhi-wei, WANG Jie, WEI Min, YANG Li, SHAO Yu-guo, JI Min, HE Qi. Comparison of therapeutic effects between different cycles of docetaxel, epirubicin and cyclophosphamide regime on adjuvant chemotherapy of locally advanced breast cancer[J]. , 2019, 39(12): 1432-.

[1]	张海燕, 储晓英. 非阿片类镇痛药应用在全身麻醉喉罩置入的乳腺癌保乳手术中的可行性[J]. 上海交通大学学报(医学版), 2021, 41(5): 637-641.
[2]	张佳玲, 张凤春, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
[3]	赵晓军, 乔志刚, 梁挺宇, 安艳玲. 乳腺癌易感基因1蛋白在脑胶质瘤中的表达及对替莫唑胺敏感性的影响[J]. 上海交通大学学报(医学版), 2021, 41(1): 118-122.
[4]	宋绪佳1，张时君2，吕文鑫1，黄林1，张言1，吴明贵1，谢少伟2. 基于单壁碳纳米管的化学 - 光热协同治疗去势抵抗性前列腺癌的研究[J]. 上海交通大学学报（医学版）, 2020, 40(4): 450-.
[5]	陈思，刘春良，赵倩，孙海鹏，刘云霞. 基于生存分析的生物信息学方法筛选乳腺癌枢纽基因和关键通路[J]. 上海交通大学学报（医学版）, 2020, 40(3): 294-.
[6]	叶欣，周晓云，杨莉，王杰，何奇. 不同年龄范围界定下的年轻乳腺癌患者的临床病理特征及预后分析[J]. 上海交通大学学报（医学版）, 2020, 40(3): 351-.
[7]	程龙1，徐五琴2，张鹏1，黄建军1，李小宁1. 下调miR-27a表达对三阴乳腺癌细胞增殖、迁移和侵袭的影响[J]. 上海交通大学学报（医学版）, 2020, 40(2): 188-.
[8]	张凤春1, 2，张硕渊3，陈天恩3，徐迎春3. PD-1/PD-L1通路在三阴性乳腺癌预后预测及治疗中的意义[J]. 上海交通大学学报（医学版）, 2020, 40(1): 128-.
[9]	何沁，张伟滨，沈宇辉. 乳腺癌脊柱转移患者预后预测模型的构建[J]. 上海交通大学学报(医学版), 2020, 40(09): 1243-1248.
[10]	张丽1，方芳1，朱智佩2, 3，申远4，柳娜5，李春波3. 简化认知行为治疗对广泛性焦虑的疗效研究[J]. 上海交通大学学报(医学版), 2020, 40(05): 619-625.
[11]	陆裕杰，金泽宇，李亚芬，沈坤炜，陈伟国，陈小松. 乳腺癌局部区域复发病灶受体状态检测及对后续治疗的指导价值[J]. 上海交通大学学报（医学版）, 2019, 39(9): 1071-.
[12]	祝利民，毛竹君，姚琼，郭玲建，沈克平. 温经祛瘀蠲痹方联合甲钴胺对化学治疗药物导致的周围神经病变的疗效观察[J]. 上海交通大学学报（医学版）, 2019, 39(7): 778-.
[13]	孙晓寅，莊志刚，傅韵，成小林. 乳腺癌 X线征象及其术后病理特征分析[J]. 上海交通大学学报（医学版）, 2019, 39(4): 398-.
[14]	杨华 1，陈青 1，邓力 1，曹烨 1，李文翔 1，徐静 1, 2，王炯元 1, 2，童汉兴 1, 2，周宇红 3，张勇 1, 2，陆维祺 1, 2. 胃肠道肿瘤患者术中联合腹腔热灌注化学治疗对术后胃肠功能恢复的影响因素分析[J]. 上海交通大学学报（医学版）, 2019, 39(4): 407-.
[15]	董晓晶 1，张男 1，甘露 1，吴怡颖 1，陈允允 1，方琼 2. 个案管理模式下老年乳腺癌患者辅助治疗依从性分析[J]. 上海交通大学学报（医学版）, 2019, 39(2): 170-.

多西他赛、表柔比星联合环磷酰胺对局部晚期乳腺癌辅助化学治疗不同周期的疗效研究

Comparison of therapeutic effects between different cycles of docetaxel, epirubicin and cyclophosphamide regime on adjuvant chemotherapy of locally advanced breast cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics